Myriad Genetics Company Leadership

MYGN Stock  USD 12.91  0.37  2.95%   
Myriad Genetics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Myriad Genetics suggests that virtually all insiders are panicking. Myriad Genetics employs about 2.7 K people. The company is managed by 18 executives with a total tenure of roughly 18 years, averaging almost 1.0 years of service per executive, having 150.0 employees per reported executive.
Mark Verratti  President
President-President Assurex Health

Myriad Genetics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2024-10-11Paul J DiazDisposed 15000 @ 22.93View
2024-09-09Heinrich DreismannDisposed 10000 @ 27.05View
2024-09-03Colleen F ReitanDisposed 46012 @ 27.95View
2024-06-03Daniel K SpiegelmanDisposed 3788 @ 22.04View
2024-05-15Paul J DiazDisposed 75000 @ 25.07View
2024-05-13Paul J DiazDisposed 57844 @ 25.13View
Monitoring Myriad Genetics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.

Myriad Genetics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Myriad Genetics' future performance. Based on our forecasts, it is anticipated that Myriad will maintain a workforce of about 1000000 employees by March 2025.
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Myriad Genetics Management Team Effectiveness

The company has return on total asset (ROA) of (0.0535) % which means that it has lost $0.0535 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.164) %, meaning that it created substantial loss on money invested by shareholders. Myriad Genetics' management efficiency ratios could be used to measure how well Myriad Genetics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of January 2025, Return On Tangible Assets is likely to grow to -0.44. In addition to that, Return On Capital Employed is likely to grow to -0.22. At this time, Myriad Genetics' Non Current Assets Total are very stable compared to the past year. As of the 30th of January 2025, Non Currrent Assets Other is likely to grow to about 14.6 M, while Total Assets are likely to drop about 670.7 M.
As of the 30th of January 2025, Common Stock Shares Outstanding is likely to drop to about 75 M. In addition to that, Net Income Applicable To Common Shares is likely to drop to about 159.7 M

Myriad Genetics Workforce Comparison

Myriad Genetics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 84,505. Myriad Genetics holds roughly 2,700 in number of employees claiming about 3% of equities under Health Care industry.

Myriad Genetics Profit Margins

The company has Profit Margin (PM) of (0.14) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.08) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.08.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.940.79
Fairly Up
Slightly volatile

Myriad Genetics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Myriad Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Myriad Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Myriad Genetics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-12-01
0.3333
2
6
 23,934 
 55,908 
2024-09-01
0.0833
1
12
 61,771 
 169,160 
2024-06-01
0.7778
7
9
 109,865 
 244,217 
2024-03-01
0.3929
11
28
 748,291 
 131,318 
2023-12-01
0.0833
1
12
 236,360 
 98,140 
2023-09-01
0.2222
2
9
 20,000 
 88,962 
2023-06-01
2.6667
8
3
 113,632 
 9,979 
2023-03-01
0.2941
10
34
 436,701 
 161,474 
2022-12-01
0.0769
1
13
 16,875 
 63,143 
2022-06-01
2.75
11
4
 156,736 
 8,193 
2022-03-01
1.3571
19
14
 791,589 
 69,695 
2021-12-01
0.3077
4
13
 35,896 
 52,107 
2021-09-01
0.4638
32
69
 1,336,551 
 1,240,627 
2021-06-01
0.9048
19
21
 249,650 
 301,674 
2021-03-01
1.75
21
12
 581,430 
 204,588 
2020-12-01
17.0
17
1
 415,309 
 2,218 
2020-09-01
0.3556
16
45
 1,241,326 
 299,913 
2020-03-01
0.5
1
2
 100,000 
 11,627 
2019-12-01
12.0
12
1
 107,663 
 1,307 
2019-09-01
0.2881
17
59
 684,500 
 490,808 
2018-12-01
3.0
6
2
 56,160 
 3,327 
2018-09-01
0.2963
16
54
 724,672 
 532,684 
2018-06-01
0.5714
16
28
 336,139 
 593,124 
2018-03-01
0.4375
7
16
 158,994 
 334,593 
2017-12-01
1.1667
7
6
 50,533 
 27,553 
2017-09-01
0.2857
10
35
 535,000 
 230,757 
2017-03-01
3.0
3
1
 6,000 
 2,631 
2016-12-01
6.0
6
1
 90,144 
 3,522 
2016-09-01
0.6364
14
22
 488,598 
 131,487 
2016-06-01
0.5
5
10
 50,619 
 99,256 
2015-12-01
0.8333
20
24
 292,899 
 436,655 
2015-09-01
0.4146
17
41
 615,828 
 543,148 
2015-06-01
1.0
1
1
 5,555 
 5,555 
2015-03-01
0.6
3
5
 45,555 
 35,275 
2014-12-01
1.6
16
10
 129,555 
 37,447 
2014-09-01
0.8333
20
24
 345,103 
 367,565 
2014-06-01
0.5625
18
32
 416,500 
 687,803 
2014-03-01
0.5738
35
61
 873,906 
 1,548,485 
2013-12-01
1.125
9
8
 219,856 
 110,214 
2013-06-01
0.5714
12
21
 305,649 
 501,360 
2012-12-01
0.6212
41
66
 735,982 
 1,133,972 
2012-09-01
0.7778
42
54
 2,019,107 
 546,830 
2012-06-01
0.6
9
15
 120,389 
 223,836 
2012-03-01
0.8209
55
67
 790,442 
 655,004 
2011-12-01
3.0
6
2
 180,000 
 1,466 
2011-09-01
13.0
13
1
 1,710,808 
 5,808 
2011-06-01
0.6444
29
45
 387,914 
 565,148 
2010-12-01
0.8333
5
6
 150,000 
 133,536 
2010-09-01
15.0
15
1
 695,000 
 5,000 
2010-06-01
1.0
4
4
 28,510 
 28,510 
2010-03-01
1.3
26
20
 680,010 
 242,181 
2009-12-01
0.6111
11
18
 239,754 
 380,900 
2009-09-01
2.2222
20
9
 671,878 
 148,893 
2009-06-01
1.0
6
6
 44,936 
 79,636 
2009-03-01
0.8367
41
49
 551,753 
 353,797 
2008-12-01
0.7692
10
13
 103,000 
 70,215 
2008-09-01
0.9412
32
34
 464,602 
 208,524 
2008-06-01
0.6667
2
3
 3,550 
 3,600 
2008-03-01
1.3571
19
14
 350,310 
 57,070 
2007-12-01
0.2857
44
154
 145,600 
 188,345 
2007-09-01
0.4444
44
99
 323,471 
 180,389 
2007-06-01
0.1
3
30
 38,750 
 116,721 
2007-03-01
1.3333
20
15
 198,526 
 67,903 
2006-12-01
0.5
6
12
 65,000 
 75,225 
2006-06-01
0.5714
4
7
 65,382 
 119,566 
2006-03-01
1.0
31
31
 289,730 
 172,830 
2005-12-01
1.0
1
1
 350.00 
 350.00 
2005-06-01
0.0286
1
35
 7,500 
 187,479 
2005-03-01
2.4
12
5
 207,000 
 17,899 
2004-12-01
2.5
5
2
 75,000 
 11,853 
2004-09-01
2.6667
8
3
 193,739 
 18,739 
2004-06-01
1.5
3
2
 17,610 
 8,530 
2004-03-01
11.0
11
1
 142,000 
 5,200 
2003-12-01
2.5
5
2
 60,490 
 490.00 

Myriad Genetics Notable Stakeholders

A Myriad Genetics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Myriad Genetics often face trade-offs trying to please all of them. Myriad Genetics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Myriad Genetics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Paul JDPresident CEOProfile
Paul DiazPresident CEOProfile
Mark VerrattiPresident-President Assurex HealthProfile
Bryan RiggsbeeCFO, Executive VP and TreasurerProfile
Justin HunterInterim SecretaryProfile
Nicole LambertChief OfficerProfile
Jennifer FoxChief OfficerProfile
Clivetty MartinezChief OfficerProfile
Pamela WongChief OfficerProfile
Shereen SolaimanChief OfficerProfile
Samraat RahaChief OfficerProfile
Natalie MunkPrincipal OfficerProfile
Scott LefflerChief OfficerProfile
Scott GleasonIR Contact OfficerProfile
Dale MuzzeyChief OfficerProfile
Kevin HaasChief OfficerProfile
Matthew ScaloSenior RelationsProfile
Glenn FarrellSenior OfficerProfile

About Myriad Genetics Management Performance

The success or failure of an entity such as Myriad Genetics often depends on how effective the management is. Myriad Genetics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Myriad management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Myriad management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.47)(0.44)
Return On Capital Employed(0.23)(0.22)
Return On Assets(0.21)(0.20)
Return On Equity(0.30)(0.29)

Myriad Genetics Workforce Analysis

Traditionally, organizations such as Myriad Genetics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Myriad Genetics within its industry.

Myriad Genetics Manpower Efficiency

Return on Myriad Genetics Manpower

Revenue Per Employee279K
Revenue Per Executive41.8M
Net Loss Per Employee97.5K
Net Loss Per Executive14.6M
Working Capital Per Employee58.4K
Working Capital Per Executive8.8M
When determining whether Myriad Genetics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Myriad Genetics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Myriad Genetics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Myriad Genetics Stock:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Myriad Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Myriad Stock, please use our How to Invest in Myriad Genetics guide.
You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Myriad Genetics. If investors know Myriad will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Myriad Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.28)
Revenue Per Share
9.205
Quarterly Revenue Growth
0.112
Return On Assets
(0.05)
Return On Equity
(0.16)
The market value of Myriad Genetics is measured differently than its book value, which is the value of Myriad that is recorded on the company's balance sheet. Investors also form their own opinion of Myriad Genetics' value that differs from its market value or its book value, called intrinsic value, which is Myriad Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Myriad Genetics' market value can be influenced by many factors that don't directly affect Myriad Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Myriad Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Myriad Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Myriad Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.